David Raben, MD, on NSCLC: Results From the PACIFIC Trial
2018 ASTRO Annual MeetingDavid Raben, MD, of the University of Colorado, discusses overall survival with durvalumab vs placebo after chemoradiotherapy in stage III non–small cell lung cancer (Abstract LBA10).
Related Videos
Thomas Galloway, MD, on Oropharyngeal Cancer: Improving Outcomes and Reducing Toxicity
Thomas Galloway, MD, of Fox Chase Cancer Center, summarizes a session on head and neck cancer that included findings on reducing oral mucositis, improving quality of life with dein...
Bhisham Chera, MD, on Oropharyngeal Cancer: Expert Perspective on Surveillance
Bhisham Chera, MD, of the University of North Carolina, discusses using human papillomavirus found in plasma circulating tumor DNA to monitor cancer recurrence in HPV-associa...
Michael Soike, MD, on Brain Metastases: Radiosurgery vs Radiotherapy
Michael Soike, MD, of Wake Forest University Medical Center, discusses results from a large multicenter study that suggests salvage stereotactic radiosurgery leads to improved overall survival comp...
Daniel R. Gomez, MD, on NSCLC: Findings From a Phase II Treatment Trial
Daniel R. Gomez, MD, of The University of Texas MD Anderson Cancer Center, discusses the final results of a phase II study on local consolidative therapy, which improved overall su...
Alan Pollack, MD, on Prostate Cancer: Results From the SPPORT Trial
Alan Pollack, MD, of the University of Miami, discusses study findings on short-term androgen-deprivation therapy with or without pelvic lymph node treatment added to prostate bed–...
